SPX3,821.55-78.56 -2.01%
DIA309.34-5.02 -1.60%
IXIC11,181.54-343.01 -2.98%

Sonnet BioTherapeutics Announces Results From A Preclinical Combination Study Of SON-1010 With anti-PD1 Checkpoint Inhibition

Tumor volume growth inhibition improvements observed with the combination of SON-1010 (IL12-FHAB) and a commercially available anti-PD1 antibody Combination of SON-1010 with anti-PD1 increased survival rate These

Benzinga · 06/09/2022 07:03
  • Tumor volume growth inhibition improvements observed with the combination of SON-1010 (IL12-FHAB) and a commercially available anti-PD1 antibody
  • Combination of SON-1010 with anti-PD1 increased survival rate
  • These data will guide future combination study designs with SON-1010 and checkpoint inhibitors